The company’s sales increased 1.2% on a constant currency basis driven by comparable sales growths at Walgreens and in the International segment, as well as US Healthcare acquisitions.
For the 52 weeks to 31 August, WBA’s operating income from continuing operations declined by 40.8% to $1.4bn.
Its adjusted operating income from continuing operations rose by 0.3% on a reported basis to $5.1bn.
WBA’s reported net earnings from continuing operations were $4.3bn, up from $2.0bn a year earlier, while its earnings per share (EPS) from continuing operations grew from $2.30 in FY21 to $5.01.
WBA CEO Rosalind Brewer said: “WBA has delivered ahead of expectations in the first year of our transformation to a consumer-centric healthcare company.
“Our resilient business achieved growth while navigating macroeconomic headwinds.”
In the fourth quarter (Q4) of FY22, WBA saw its sales from continuing operations drop by 5.3% to $32.4bn compared with the corresponding period of FY21.
Operating loss from the company’s continuing operations was $822m, against an operating income of $910m for Q4 2021, and its net loss from continuing operations in the quarter was $415m.
WBA recorded a loss from continuing operations of $0.48 to a share in Q4 2022, compared to $0.89 in the same period of the prior year.
For fiscal 2023 (FY23), WBA expects its adjusted EPS to be between $4.45 and $4.65.
Brewer added: “FY23 will be a year of accelerating core growth and rapidly scaling our US Healthcare business.
“Our execution to date provides us visibility and confidence to increase the long-term outlook for our next growth engine and reconfirm our path to low teens adjusted EPS growth.”